Stock listing

NASDAQ:MREO Mereo BioPharma Group plc Stock

Home listing (NASDAQ) of Mereo BioPharma Group plc

Follow Mereo BioPharma Group plc into a list and get an email when it puts out news.

Share price · NASDAQ:MREO

$0.26 USD -0.03 (-10.1%)

Close on Nov 20, 2026

Past year -85.5% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.26 – $0.277 USDNov 20, 2026
Volume
1.08M sharesNov 20, 2026
Market cap
$41.52M USDAt the close on Nov 20, 2026 · price × 159.7M shares outstanding
52-week range
$0.20 – $2.37 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$378,995 USDMedian day 1.04M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Mereo BioPharma Group plc logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:MREO · Home$0.26 USD-0.029 (-10.1%)1,081,184$0.275$0.277$0.26$0.289Close on Nov 20, 2026
LSE:0A9G$0.266 USD-0.014 (-5.2%)9,908$0.278$0.278$0.263$0.280Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:MREO · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.26-0.029-10.1%$0.275$0.277$0.261,081,184
$0.289+0.015+5.4%$0.266$0.30$0.266859,631
$0.275-0.03-10.0%$0.301$0.305$0.2651,037,251
$0.305-0.003-0.8%$0.298$0.307$0.297625,526
$0.308+0.003+0.8%$0.302$0.318$0.297893,672
$0.305-0.002-0.5%$0.297$0.313$0.29698,057
$0.307+0.009+2.9%$0.299$0.31$0.299387,887
$0.298+0.003+0.9%$0.287$0.304$0.281,774,949
$0.295+0.012+4.3%$0.287$0.305$0.2851,724,752
$0.283+0.003+0.9%$0.271$0.285$0.271655,613
$0.28-0.023-7.5%$0.30$0.313$0.277925,396
$0.303+0.012+4.2%$0.297$0.307$0.281529,606
$0.291+0.001+0.3%$0.289$0.298$0.285272,436
$0.290.000.0%$0.286$0.299$0.28477,594
$0.29-0.012-4.0%$0.297$0.315$0.28543,700
$0.302+0.005+1.7%$0.30$0.325$0.2871,134,100
$0.297+0.005+1.7%$0.281$0.303$0.281113,600
$0.292+0.017+6.2%$0.286$0.299$0.278291,300
$0.275-0.007-2.5%$0.279$0.287$0.275313,200
$0.282-0.005-1.7%$0.281$0.287$0.275519,000
$0.287-0.004-1.4%$0.288$0.294$0.283381,700
$0.291-0.004-1.4%$0.301$0.314$0.289330,000
$0.295-0.007-2.3%$0.308$0.318$0.294488,400
$0.302-0.001-0.3%$0.31$0.32$0.30530,900
$0.303-0.006-1.9%$0.301$0.309$0.293722,300
$0.309-0.001-0.3%$0.30$0.32$0.297529,300
$0.31-0.01-3.1%$0.31$0.323$0.30890,200
$0.32+0.005+1.6%$0.311$0.321$0.2971,267,900
$0.315-0.035-10.0%$0.35$0.364$0.311,329,200
$0.35-0.025-6.7%$0.38$0.388$0.3431,222,300
$0.375+0.022+6.2%$0.35$0.383$0.3411,063,600
$0.353+0.003+0.9%$0.355$0.367$0.3461,133,600
$0.35-0.038-9.8%$0.398$0.399$0.351,269,000
$0.388+0.008+2.1%$0.37$0.403$0.3632,470,300
$0.38+0.013+3.5%$0.385$0.389$0.361880,400
$0.367-0.035-8.7%$0.399$0.401$0.3641,602,500
$0.402+0.029+7.8%$0.37$0.423$0.373,067,200
$0.373+0.003+0.8%$0.366$0.392$0.3611,549,700
$0.370.000.0%$0.371$0.381$0.3551,744,300
$0.37+0.032+9.5%$0.334$0.372$0.332,095,400
$0.338-0.002-0.6%$0.345$0.349$0.3251,305,900
$0.34+0.024+7.6%$0.318$0.373$0.3133,921,500
$0.316+0.026+9.0%$0.291$0.32$0.2912,320,600
$0.29-0.013-4.3%$0.303$0.31$0.2891,929,700
$0.303+0.013+4.5%$0.28$0.31$0.282,739,800
$0.29+0.024+9.0%$0.269$0.297$0.2681,744,800
$0.266-0.019-6.7%$0.281$0.29$0.2611,519,000
$0.285+0.005+1.8%$0.28$0.29$0.271886,700
$0.280.000.0%$0.28$0.289$0.2721,185,900
$0.28+0.035+14.3%$0.26$0.293$0.265,109,900
$0.245+0.002+0.8%$0.243$0.249$0.24699,500
$0.243-0.012-4.7%$0.256$0.256$0.2392,951,200
$0.255+0.005+2.0%$0.25$0.259$0.245803,800
$0.25-0.022-8.1%$0.272$0.272$0.2481,333,000
$0.272+0.005+1.9%$0.264$0.28$0.263876,900
$0.267-0.01-3.6%$0.27$0.284$0.263805,000
$0.277+0.01+3.7%$0.27$0.288$0.271,559,200
$0.267+0.014+5.5%$0.253$0.288$0.2531,311,000
$0.253-0.019-7.0%$0.266$0.274$0.2521,556,500
$0.272-0.006-2.2%$0.288$0.288$0.2671,421,700
$0.278-0.004-1.3%$0.289$0.289$0.2761,017,000
$0.282-0.008-2.7%$0.288$0.293$0.2811,154,252
$0.29-0.001-0.2%$0.29$0.294$0.285799,385
$0.29-0.003-1.0%$0.303$0.306$0.29714,700
$0.293-0.019-6.1%$0.308$0.308$0.293754,700
Ticker
NASDAQ:MREO
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Mereo BioPharma Group plc news

Mereo BioPharma Group plc on 6ix

Sector
Health care
Industry
Biotechnology
News releases
2 in the last 12 months · 2 in all · newest Nov 9, 2026 · oldest 2026
Decks
36 decks · latest November 2026

Where Mereo BioPharma Group plc is listed

ListingExchangeCountryCurrency
NASDAQ:MREO · Home listing · This pageNASDAQUnited StatesUSD
LSE:0A9GLSEUnited KingdomUSD

Valuation

EV/sales 20.0× against a median of 17.1×: 3rd lowest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$16.00M USD
P/E
Loss
EV/sales
20.0×
EV/EBITDA
Negative EBITDA
Price/book
1.8×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta vs S&P 500
1.34

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Mereo BioPharma Group plc · NASDAQ:MREOUS$41.52MUS$16.00Mn/a20.0×n/a1.8×n/a0.0×1.34
Spero Therapeutics, Inc. · NASDAQ:SPROUS$43.23M−US$63.10Mn/a−1.5×n/a55.4×−71.0%2.0×1.68
Eloxx Pharmaceuticals, Inc. · NASDAQ:ELOXUS$43.15M−US$1.28Mn/an/an/a1.1×n/a0.3×n/a
Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBPUS$42.45M−US$68.98Mn/an/an/a0.5×n/a0.1×1.85
Arecor Therapeutics PLC · LSE:ARECUS$42.37MUS$38.32M48.8×17.1×n/a8.8×38.7%0.0×n/a
OS Therapies Incorporated · AMEX:OSTXUS$42.00MUS$41.57Mn/an/an/an/an/an/a1.70
Advagene Biopharma Co., Ltd. · TPEX:6709US$41.89MUS$32.03Mn/an/an/a3.9×n/a0.0×n/a
Biomea Fusion, Inc. · NASDAQ:BMEAUS$41.75MUS$15.85Mn/an/an/a5.5×n/a0.1×1.14
Prescient Therapeutics Limited · ASX:PTXUS$41.64MUS$35.80Mn/an/an/a4.4×n/a0.0×n/a
Elicio Therapeutics, Inc. · NASDAQ:ELTXUS$41.05MUS$19.78Mn/an/an/a2.2×n/a0.5×1.81
MiNK Therapeutics, Inc. · NASDAQ:INKTUS$40.93MUS$33.46Mn/a167×n/an/an/an/a0.81
Median of the othersUS$41.94MUS$25.90M48.8×17.1×4.2×−16.1%0.1×1.69

Forecasts

4 strong buy · 1 buy · 2 hold · 1 sell · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
1.96 USD · Analysts' mean
EPS, year to Dec 2026
-0.044 · 5 analysts

Team and board

Officers

OfficerRole
Denise Scots-KnightChief Executive Officer
Christine FoxChief Financial Officer
Charles SermonGeneral Counsel and Business Development
Bal LallyVice President, Head of HR
Bharti NavsariwalaVice President, Head of Regulatory Affairs
Bo KaraSenior Vice President, Head of Pharmaceutical Development
Jackie ParkinSenior Vice President, Therapeutic Head
Ogün SazovaVice President, Clinical Development and Medical Affairs
John LewickiChief Scientific Officer
Wills Hughes-WilsonChief Patient Access and Commercial Planning

Board

DirectorRole
Michael WyzgaChairman of the Board
Anders EkblomNon-Executive Director
Daniel ShamesNon-Executive Director
Deepa PakianathanNon-Executive Director
Jeremy BenderNon-Executive Director
Justin RobertsNon-Executive Director
Marc YoskowitzNon-Executive Director
Pierre JacquetNon-Executive Director

Events

Next results
Mar 18, 2027 (expected)
QuarterResultsShare move
Q3 2026Nov 9, 2026 · Before open+4.3%
Q2 2026Aug 11, 2026 · Before open+12.5%
Q1 2026Apr 1, 2026−3.0%
Q4 2025Mar 19, 2026 · Before open+2.6%
Q3 2025Nov 10, 2025 · After close+5.7%
Q2 2025Aug 12, 2025 · Before open+9.2%
Q1 2025May 13, 2025 · Before open−7.2%
Q4 2024Mar 26, 2025+2.5%
Q3 2024Nov 12, 2024 · Before open−4.2%
Q2 2024Aug 13, 2024 · Before open+1.1%
All 20 quarters
QuarterResultsShare move
Q1 2024May 15, 2024 · After close+3.1%
Q4 2023Mar 27, 2024+11.9%
Q3 2023Nov 17, 2023 · After close+5.3%
Q2 2023Sep 7, 2023 · Before open+1.8%
Q1 2023May 31, 2023+3.8%
Q4 2022Mar 28, 2023 · After close−2.4%
Q3 2022Nov 1, 2022 · After close−7.0%
Q4 2021Mar 30, 2022 · After close+7.7%
Quarter to Jun 30, 2021Aug 11, 2021−9.6%
Quarter to Mar 31, 2021Jun 2, 2021+4.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck49 slidesNovember 2026
Investor Presentation (October 2026)Investor deck49 slidesOctober 2026
Investor Presentation (May 2026)Investor deck52 slidesMay 2026
J.P. Morgan Conference (January 2026)Conference26 slidesJan 12, 2026
Investor Presentation (January 2025)Investor deck50 slidesJanuary 2025
Investor Presentation (November 2024)Investor deck54 slidesNovember 2024
Investor Presentation (October 2024)Investor deck52 slidesOctober 2024
Investor Presentation (August 2024)Investor deck47 slidesAugust 2024
Investor Presentation (March 2024)Investor deck52 slidesMarch 2024
Investor Presentation (January 2024)Investor deck50 slidesJanuary 2024
All 36 decks
DeckKindSlidesDate
Investor Presentation (October 2023)Investor deck44 slidesOctober 2023
Investor Presentation (September 2023)Investor deck39 slidesSeptember 2023
Investor Presentation (June 2023)Investor deck35 slidesJune 2023
Investor Presentation (March 2023)Investor deck26 slidesMarch 2023
Investor Presentation (January 2023)Investor deck21 slidesJanuary 2023
Investor Presentation (December 2022)Investor deck21 slidesDecember 2022
Investor Presentation (October 2022)Investor deck18 slidesOctober 2022
Investor Presentation (September 2022)Investor deck18 slidesSeptember 2022
Investor Presentation (July 2022)Investor deck18 slidesJuly 2022
Investor Presentation (June 2022)Investor deck30 slidesJune 2022
Investor Presentation (May 2022)Investor deck30 slidesMay 2022
Investor Presentation (April 2022)Investor deck30 slidesApril 2022
Technical Presentation (March 2022)Technical20 slidesMar 14, 2022
Investor Presentation (March 2022)Investor deck34 slidesMarch 2022
Investor Presentation (February 2022)Investor deck34 slidesFebruary 2022
Investor Presentation (January 2022)Investor deck34 slidesJanuary 2022
Investor Presentation (September 2021)Investor deck53 slidesSeptember 2021
Investor Presentation (July 2021)Investor deck52 slidesJuly 2021
Investor Day (May 2021)Investor day112 slidesMay 13, 2021
Investor Presentation (May 2021)Investor deck45 slidesMay 2021
Investor Day (November 2020)Investor day96 slidesNov 24, 2020
Investor Presentation (November 2020)Investor deck35 slidesNovember 2020
Investor Presentation (October 2020)Investor deck41 slidesOctober 2020
Investor Presentation (September 2020)Investor deck40 slidesSeptember 2020
H1 2019 Earnings PresentationEarnings10 slidesSep 17, 2019
H1 2016 Earnings PresentationEarnings27 slidesSep 16, 2016

Open Decks

IPO

Withdrawn on Feb 21, 2019. Filed with the SEC to go public on Mar 23, 2018.

Shares offered
15,892,917 ordinary shares
Underwriters
Cowen, BMO Capital Markets, RBC Capital Markets, JMP Securities, Cantor Fitzgerald Europe · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceDec 1, 2017
Filed publiclyMar 23, 2018
Amended onceApr 9, 2018
Filing withdrawnFeb 21, 2019

Open IPO · From the cover of the amended prospectus (F-1/A) filed Apr 9, 2018

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue500.0K010.0M049.2M393.0K-122.0K0-3.29M0
Cost of revenue133.0K1.09M2.57M24.2M2.05M2.01M22.7M34.6M24.6M
Gross profit367.0K-1.09M7.43M25.0M-2.05M-2.01M-22.7M-37.9M-24.6M
Research and development17.8M20.9M17.4M29.5M31.8M21.0M30.1M22.7M34.6M24.6M
Selling, general and administrative23.0M26.4M18.4M21.5M21.2M15.9M12.5M10.7M11.6M
Operating income-40.1M-47.4M-28.4M-54.4M-28.3M-48.2M-50.4M-35.2M-45.3M-36.2M
Depreciation and amortization157.0K143.0K171.0K181.0K866.5K2.05M2.01M37.8K36.1K32.9K
EBITDA-40.0M-47.2M-28.2M-54.2M-27.4M-46.1M-48.4M-35.2M-45.3M-36.1M
Interest expense255.0K1.37M2.88M4.17M5.22M6.38M3.50M2.36M1.09M179.8K
Income before tax-41.9M-43.3M-30.0M-42.9M19.2M-213.4M-52.5M-37.3M-47.0M-33.7M
Income tax00-532.0K-718.0K2.05M-3.62M-8.00M-5.28M-8.15M-5.33M
Net income-41.9M-43.3M-29.5M-42.2M17.2M-209.8M-44.5M-32.0M-38.8M-28.4M
Earnings per share, basic-0.05-0.06-0.04-0.070.15-3.10-2.49-2.25-2.81-0.63
Earnings per share, diluted-0.05-0.06-0.04-0.07

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents41.0M69.8M57.4M68.2M126.7M31.3M20.9M25.0M50.0M53.6M
Short-term investments769.5K748.0K720.6K2.50M2.50M0
Receivables1.98M3.25M3.73M1.42M1.02M12.0M5.89M509.4K6.10M
Inventory1.25M-1.82M-4.64M-12.0M-293.3K-2.50M-53.9M
Current assets45.0M74.8M63.8M75.2M134.3M40.7M40.3M34.5M63.2M60.8M
Property, plant and equipment137.0K257.0K405.0K551.0K2.53M1.57M11.6M149.0K153.4K173.9K
Goodwill000
Total assets45.9M76.4M66.5M77.4M171.0M86.1M114.5M67.3M96.3M86.8M
Accounts payable1.33M2.44M2.35M3.49M3.09M4.33M8.14M5.57M2.64M3.21M
Current liabilities4.30M13.8M9.49M24.4M17.0M11.7M39.6M16.2M9.62M3.21M
Long-term debt4.39M14.4M16.1M5.37M14.6M18.8M3.13M
Total debt202.0K6.43M5.95M22.7M24.5M42.9M21.5M20.8M3.13M
Total liabilities5.00M15.4M16.0M26.0M51.9M106.6M61.2M34.5M33.9M7.51M
Shareholders' equity40.9M61.0M50.5M51.4M119.0M-20.5M53.3M32.8M62.5M79.3M
Shares outstanding798.5M798.5M798.1M795.0M116.7M67.8M17.9M14.2M13.8M44.8M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-31.0M-32.8M-21.1M-48.8M-7.07M-38.6M-60.2M-23.1M-32.1M-27.4M
Capital spending-20.0K00-13.0K-722.1K-21.8K-27.5K-35.5K-2.30M-3.47K
Free cash flow-31.0M-32.8M-21.1M-48.8M-7.79M-38.6M-60.3M-23.2M-34.4M-27.4M
Cash from investing-20.0K-699.0K-419.0K1.99M-568.2K2.04M56.8M251.6K-3.74M372.6K
Cash from financing327.0K46.1M7.97M200.0K104.8M47.3M-7.49M-2.07M33.7M68.4M
Dividends paid000000
Share buybacks00-1.31M-306.8K15.0M67.9M
Change in cash-30.7M12.4M-10.8M-46.6M95.6M9.71M-11.4M-25.0M-3.53M41.3M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
8-K · Current reportNov 9, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 28, 2026Big-stake noticeSEC
8-K · Current reportAug 19, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
8-K · Current reportAug 11, 2026ResultsSEC
8-K · Current reportAug 11, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 14, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportMay 14, 2026Meeting outcomeSEC
8-K/A · Current report, amendedMay 12, 2026ResultsSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
8-K · Current reportMay 12, 2026Acquisition or disposalSEC
ARS · Annual report to shareholdersApr 9, 2026Annual reportSEC
DEF 14A · Proxy statementApr 9, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementMar 27, 2026Meeting noticeSEC
8-K · Current reportMar 27, 2026Management or board changeSEC
10-K · Annual reportMar 19, 2026Annual reportSEC
8-K · Current reportMar 19, 2026ResultsSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
8-K · Current reportFeb 17, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
S-8 · Registration statement for employee plansFeb 2, 2026Offer documentSEC
8-K · Current reportJan 12, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeJan 9, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 6, 2026Big-stake noticeSEC
8-K · Current reportDec 29, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
8-K · Current reportNov 10, 2025ResultsSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
8-K · Current reportJul 10, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeJun 11, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2025Big-stake noticeSEC
8-K · Current reportMay 14, 2025Meeting outcomeSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
8-K · Current reportMay 13, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 8, 2025Annual reportSEC
DEF 14A · Proxy statementApr 8, 2025Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeApr 4, 2025Big-stake noticeSEC
10-K · Annual reportMar 26, 2025Annual reportSEC
8-K · Current reportMar 26, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
S-8 · Registration statement for employee plansJan 23, 2025Offer documentSEC
8-K · Current reportJan 13, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedDec 6, 2024Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveDec 5, 2024Other filingsSEC
424B3 · ProspectusDec 4, 2024Offer documentSEC
CORRESP · Letter to the SECDec 3, 2024Other filingsSEC
UPLOAD · Letter from the SECDec 2, 2024Other filingsSEC
S-3 · Registration statementNov 25, 2024Offer documentSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
4 · Change in ownershipSep 16, 2024Insider tradeSEC
4 · Change in ownershipSep 16, 2024Insider tradeSEC
4 · Change in ownershipSep 16, 2024Insider tradeSEC
4 · Change in ownershipSep 16, 2024Insider tradeSEC
4 · Change in ownershipSep 16, 2024Insider tradeSEC
4 · Change in ownershipSep 13, 2024Insider tradeSEC
4 · Change in ownershipSep 13, 2024Insider tradeSEC
4 · Change in ownershipSep 13, 2024Insider tradeSEC
4 · Change in ownershipSep 13, 2024Insider tradeSEC
4 · Change in ownershipSep 13, 2024Insider tradeSEC
144 · Notice of proposed saleSep 12, 2024Other filingsSEC
144 · Notice of proposed saleSep 12, 2024Other filingsSEC
144 · Notice of proposed saleSep 12, 2024Other filingsSEC
144 · Notice of proposed saleSep 12, 2024Other filingsSEC
144 · Notice of proposed saleSep 12, 2024Other filingsSEC
4 · Change in ownershipAug 23, 2024Insider tradeSEC
144 · Notice of proposed saleAug 22, 2024Other filingsSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
8-K · Current reportAug 13, 2024ResultsSEC
SC 13G · Big-stake noticeJul 11, 2024Big-stake noticeSEC
4 · Change in ownershipJun 27, 2024Insider tradeSEC
4 · Change in ownershipJun 27, 2024Insider tradeSEC
4 · Change in ownershipJun 27, 2024Insider tradeSEC
4 · Change in ownershipJun 27, 2024Insider tradeSEC
4 · Change in ownershipJun 27, 2024Insider tradeSEC
4 · Change in ownershipJun 25, 2024Insider tradeSEC
4 · Change in ownershipJun 25, 2024Insider tradeSEC
4 · Change in ownershipJun 25, 2024Insider tradeSEC
4 · Change in ownershipJun 25, 2024Insider tradeSEC
4 · Change in ownershipJun 25, 2024Insider tradeSEC
144/A · Notice of proposed sale, amendedJun 24, 2024Other filingsSEC
144/A · Notice of proposed sale, amendedJun 24, 2024Other filingsSEC
144/A · Notice of proposed sale, amendedJun 24, 2024Other filingsSEC
144/A · Notice of proposed sale, amendedJun 24, 2024Other filingsSEC
144/A · Notice of proposed sale, amendedJun 24, 2024Other filingsSEC
144 · Notice of proposed saleJun 20, 2024Other filingsSEC
144 · Notice of proposed saleJun 20, 2024Other filingsSEC
144 · Notice of proposed saleJun 20, 2024Other filingsSEC
144 · Notice of proposed saleJun 20, 2024Other filingsSEC
144 · Notice of proposed saleJun 20, 2024Other filingsSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedJun 17, 2024Big-stake noticeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
8-K · Current reportJun 14, 2024Material contractSEC
424B5 · ProspectusJun 14, 2024Offer documentSEC
8-K · Current reportJun 11, 2024Current reportSEC
4/A · Change in ownership, amendedJun 11, 2024Insider tradeSEC
EFFECT · Notice that a registration is effectiveMay 28, 2024Other filingsSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
144 · Notice of proposed saleMay 23, 2024Other filingsSEC
8-K · Current reportMay 23, 2024Meeting outcomeSEC
CORRESP · Letter to the SECMay 21, 2024Other filingsSEC
UPLOAD · Letter from the SECMay 20, 2024Other filingsSEC
S-3 · Registration statementMay 15, 2024Offer documentSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
8-K · Current reportMay 15, 2024ResultsSEC
ARS · Annual report to shareholdersApr 24, 2024Annual reportSEC
DEF 14A · Proxy statementApr 24, 2024Meeting noticeSEC
SC 13D/A · Big-stake notice, amendedApr 16, 2024Big-stake noticeSEC
8-K · Current reportApr 15, 2024Material contractSEC
10-K · Annual reportMar 27, 2024Annual reportSEC
8-K · Current reportMar 27, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 9, 2024Insider tradeSEC
4 · Change in ownershipFeb 9, 2024Insider tradeSEC
4 · Change in ownershipFeb 9, 2024Insider tradeSEC
4 · Change in ownershipFeb 9, 2024Insider tradeSEC
4 · Change in ownershipFeb 9, 2024Insider tradeSEC
4 · Change in ownershipFeb 9, 2024Insider tradeSEC
4 · Change in ownershipFeb 9, 2024Insider tradeSEC
4 · Change in ownershipFeb 9, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 6, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 5, 2024Big-stake noticeSEC
4 · Change in ownershipJan 26, 2024Insider tradeSEC
4 · Change in ownershipJan 26, 2024Insider tradeSEC
4 · Change in ownershipJan 26, 2024Insider tradeSEC
4 · Change in ownershipJan 26, 2024Insider tradeSEC
4 · Change in ownershipJan 26, 2024Insider tradeSEC
S-8 · Registration statement for employee plansJan 23, 2024Offer documentSEC
8-K · Current reportJan 8, 2024Current reportSEC
3 · Initial statement of ownershipJan 2, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2024Insider tradeSEC
8-A12B/A · Registration of shares for listing on an exchange, amendedDec 18, 2023Other filingsSEC
6-K · Report of a foreign issuerDec 18, 2023Current reportSEC
6-K · Report of a foreign issuerNov 29, 2023Current reportSEC
SC 13D/A · Big-stake notice, amendedNov 20, 2023Big-stake noticeSEC
6-K · Report of a foreign issuerNov 16, 2023Current reportSEC
SC 13D/A · Big-stake notice, amendedNov 15, 2023Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedNov 13, 2023Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedNov 8, 2023Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedNov 6, 2023Big-stake noticeSEC

This page holds 200 of 441 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Mereo BioPharma Group plc’s releases

Common shares
159,690,973
Fully diluted
159,690,973

Fully diluted

LineShares
Common shares159,690,973

Share count over time

CountShares
Nov 22, 2026159,690,973

Open Cap table

Shareholders

HolderSharesOf the companyValueAs of
Rubric Capital Management LP15.3M1.9%US$6.15MSep 30, 2026
683 Capital Management, LLC14.3M1.8%US$5.75MSep 30, 2026
Defilade Capital Management, L.P.7.56M0.95%US$3.04MSep 30, 2026
Bank of America5.34M0.67%US$2.15MSep 30, 2026
Tejara Capital Ltd2.01M0.25%US$810KSep 30, 2026
Newtyn Management, LLC1.55M0.19%US$623KSep 30, 2026
Knoll Capital Management, LLC1.55M0.19%US$621KSep 30, 2026
Nantahala Capital Management, LLC1.26M0.16%US$505KSep 30, 2026
Two Sigma989K0.12%US$398KSep 30, 2026
Wealthspire Advisors, LLC765K0.10%US$308KSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Cantor Fitzgerald, L. P.750K0.09%US$302KSep 30, 2026
Shay Capital LLC750K0.09%US$302KSep 30, 2026
Jane Street538K0.07%US$216KSep 30, 2026
Nomura531K0.07%US$213KSep 30, 2026
Hrt Financial LP377K0.05%US$151KSep 30, 2026
UBS361K0.05%US$145KSep 30, 2026
Rangeley Capital, LLC329K0.04%US$132KSep 30, 2026
Renaissance Technologies160K0.02%US$64,367Sep 30, 2026
Group One Trading LLC131K0.02%US$52,564Sep 30, 2026
Susquehanna131K0.02%US$52,463Sep 30, 2026
Significant Wealth Partners LLC129K0.02%US$52,035Sep 30, 2026
XTX Topco Ltd112K0.01%US$45,225Sep 30, 2026
James J. Burns & Company, LLC95,4000.01%US$38,351Sep 30, 2026
Clear Harbor Asset Management, LLC85,5000.01%US$34,807Sep 30, 2026
JPMorgan74,677<0.01%US$27,869Sep 30, 2026
BlackRock69,615<0.01%US$27,985Sep 30, 2026
Citadel42,646<0.01%US$17,144Sep 30, 2026
Virtu Financial LLC34,089<0.01%US$14,000Sep 30, 2026
Rhumbline Advisers26,784<0.01%US$10,763Sep 30, 2026
Centiva Capital, LP25,000<0.01%US$10,050Sep 30, 2026
Marshall Wace, LLP24,048<0.01%US$9,619Sep 30, 2026
Engineers Gate Manager LP23,953<0.01%US$9,629Sep 30, 2026
NFSG Corp18,750<0.01%US$7,538Sep 30, 2026
OneDigital Investment Advisors LLC18,300<0.01%US$7,357Sep 30, 2026
BMO17,500<0.01%US$7,035Sep 30, 2026
Morgan Stanley16,558<0.01%US$6,656Sep 30, 2026
StoneX Group Inc.15,479<0.01%US$4,508Sep 30, 2026
IHT Wealth Management, LLC15,000<0.01%US$6,030Sep 30, 2026
Mml Investors Services, LLC12,200<0.01%US$4,904Sep 30, 2026
Simplex Trading, LLC12,070<0.01%US$4,852Sep 30, 2026
Astoria Portfolio Advisors LLC.10,000<0.01%US$4,020Sep 30, 2026
Citigroup Inc8,675<0.01%US$3,487Sep 30, 2026
Arax Advisory Partners5,819<0.01%US$2,339Sep 30, 2026
Osaic Holdings, Inc.2,550<0.01%US$962Sep 30, 2026
Rockefeller Capital Management L.P.2,000<0.01%US$804Sep 30, 2026
Allworth Financial LP1,500<0.01%US$603Sep 30, 2026
Markowski Investments1,500<0.01%US$603Sep 30, 2026
Sit Investment Associates Inc970<0.01%Sep 30, 2026
New England Capital Financial Advisors LLC300<0.01%US$121Sep 30, 2026
Wells Fargo230<0.01%US$92Sep 30, 2026

This page holds 50 of 53 holders. Open Shareholders

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Annalisa Jenkins
Other companies: Skye Bioscience, Inc. (Director · Since at least Feb 29, 2024); COMPASS Pathways Plc (Director · Since at least Jan 1, 2022); Serina Therapeutics, Inc. (Director · Nov 27, 2018 – Jun 21, 2021 · Past); Tectonic Therapeutic, Inc. (Director · Jun 20, 2018 – Jun 6, 2023 · Past); Dimension Therapeutics (President and CEO, Director · Oct 21, 2015 – Nov 7, 2017 · Past); Ardelyx, Inc. (Director · Apr 20, 2015 – Jun 13, 2019 · Past)
Director · Since at least Jan 1, 2024
Jeremy Bender
Other companies: Bicara Therapeutics Inc. (Director · Since at least Jul 28, 2026); Aura Biosciences, Inc. (Director · Since at least Jul 7, 2026); Day One Biopharmaceuticals Inc (CHIEF EXECUTIVE OFFICER, Director · Since at least May 26, 2021); Fusion Pharmaceuticals Inc (Director · Oct 16, 2023 – Jun 4, 2024 · Past)
Non-Executive Director · Since at least Jan 1, 2024
Michael Wyzga
Other companies: X4 Pharmaceuticals, Inc. (Director · Since at least Jun 9, 2025); Tvardi Therapeutics, Inc. (Board Member · Since at least Apr 15, 2025)
Director · Since at least Feb 26, 2026
Justin H. Roberts
Other companies: TherapeuticsMD, Inc. (Board Member · Since at least Aug 23, 2022)
Non-Executive Director · Since at least Jan 1, 2024
Pierre Jacquet
Other companies: EXACT Sciences Corporation (Director · Jun 9, 2022 – Jun 8, 2023 · Past)
Non-Executive Director · Since at least Jan 1, 2024
Alexandra Hughes-WilsonSee Remarks · Since at least Jan 1, 2024
Anders EkblomNon-Executive Director · Since at least Nov 5, 2026
Bal LallyVice President, Head of HR · Since at least Nov 4, 2026
Bharti NavsariwalaVice President, Head of Regulatory Affairs · Since at least Nov 4, 2026
Bo KaraSenior Vice President, Head of Pharmaceutical Development · Since at least Nov 4, 2026
All 20 people
PersonSeat
Charles SermonGeneral Counsel and Business Development · Since at least Jan 1, 2024
Christine FoxChief Financial Officer · Since at least Jan 1, 2024
Daniel ShamesNon-Executive Director · Since at least Nov 5, 2026
Deepa PakianathanNon-Executive Director · Since at least Nov 5, 2026
Denise Scots-KnightChief Executive Officer · Since at least Mar 19, 2026
Jackie ParkinSenior Vice President, Therapeutic Head · Since at least Nov 4, 2026
John LewickiChief Scientific Officer · Since at least Nov 4, 2026
Marc YoskowitzNon-Executive Director · Since at least Nov 5, 2026
Ogün SazovaVice President, Clinical Development and Medical Affairs · Since at least Nov 4, 2026
Wills Hughes-WilsonChief Patient Access and Commercial Planning · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Mereo BioPharma Group plc.